334 related articles for article (PubMed ID: 35630534)
1. Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment.
Yin R; Xu Y; Wang X; Yang L; Zhao D
Molecules; 2022 May; 27(10):. PubMed ID: 35630534
[TBL] [Abstract][Full Text] [Related]
2. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis.
Min SH; Yoon JH; Moon SJ; Hahn S; Cho YM
Sci Rep; 2018 Mar; 8(1):4466. PubMed ID: 29535389
[TBL] [Abstract][Full Text] [Related]
3. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
4. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes.
Zhou J; Liu X; Chou OH; Li L; Lee S; Wong WT; Zhang Q; Chang C; Liu T; Tse G; Jing F; Cheung BMY
Rheumatology (Oxford); 2023 Apr; 62(4):1501-1510. PubMed ID: 36066415
[TBL] [Abstract][Full Text] [Related]
5. Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment.
Florentin M; Kostapanos MS; Papazafiropoulou AK
World J Diabetes; 2022 Feb; 13(2):85-96. PubMed ID: 35211246
[TBL] [Abstract][Full Text] [Related]
6. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
[TBL] [Abstract][Full Text] [Related]
7. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.
Deacon CF
Nat Rev Endocrinol; 2020 Nov; 16(11):642-653. PubMed ID: 32929230
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms.
Zakaria EM; Tawfeek WM; Hassanin MH; Hassaballah MY
Naunyn Schmiedebergs Arch Pharmacol; 2022 Nov; 395(11):1357-1372. PubMed ID: 35945358
[TBL] [Abstract][Full Text] [Related]
10. Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients.
Anderson S; Cotiguala L; Tischer S; Park JM; McMurry K
Ann Pharmacother; 2021 Apr; 55(4):496-508. PubMed ID: 32795145
[TBL] [Abstract][Full Text] [Related]
11. Role of DPP4 and DPP4i in Glucose Homeostasis and Cardiorenal Syndrome.
Panda SP
Endocr Metab Immune Disord Drug Targets; 2023; 23(2):179-187. PubMed ID: 35642117
[TBL] [Abstract][Full Text] [Related]
12. Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes.
Libianto R; Davis TM; Ekinci EI
Med J Aust; 2020 Feb; 212(3):133-139. PubMed ID: 31910303
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2016; 9(2):229-40. PubMed ID: 26589238
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
Kalra S
J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.
Moore KB; Saudek CD
Am J Ther; 2008; 15(5):484-91. PubMed ID: 18806525
[TBL] [Abstract][Full Text] [Related]
16. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Yoshida K; Kiuchi S; Ikenaga Y; Nakamaru Y; Hikida K; Saito A; Arakawa K; Oka K; Ueta K; Shiotani M
J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
[TBL] [Abstract][Full Text] [Related]
17. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
Savarese G; D'Amore C; Federici M; De Martino F; Dellegrottaglie S; Marciano C; Ferrazzano F; Losco T; Lund LH; Trimarco B; Rosano GM; Perrone-Filardi P
Int J Cardiol; 2016 Oct; 220():595-601. PubMed ID: 27390996
[TBL] [Abstract][Full Text] [Related]
18. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.
Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L
Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199
[TBL] [Abstract][Full Text] [Related]
19. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Guthrie RM
Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
